Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Payables (2020 - 2025)

Historic Payables for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $1.1 million.

  • Insight Molecular Diagnostics' Payables rose 720.81% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 720.81%. This contributed to the annual value of $2.3 million for FY2024, which is 13913.96% up from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Payables of $1.1 million as of Q3 2025, which was up 720.81% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Payables peaked at $5.3 million during Q1 2021, and registered a low of $908000.0 during Q1 2024.
  • Moreover, its 5-year median value for Payables was $1.9 million (2021), whereas its average is $2.0 million.
  • In the last 5 years, Insight Molecular Diagnostics' Payables tumbled by 7017.59% in 2023 and then soared by 15099.12% in 2025.
  • Insight Molecular Diagnostics' Payables (Quarter) stood at $2.1 million in 2021, then decreased by 12.85% to $1.8 million in 2022, then crashed by 47.55% to $953000.0 in 2023, then surged by 139.14% to $2.3 million in 2024, then tumbled by 53.66% to $1.1 million in 2025.
  • Its Payables stands at $1.1 million for Q3 2025, versus $1.3 million for Q2 2025 and $2.3 million for Q1 2025.